Grateful for the leadership of President. Jeffrey Tsai at Asia University and so excited for what’s ahead 🚀
Press release:
tinyurl.com/fdn8ckd9

Dr. Haghighi is Chief Executive and Director, Harvard Medical School International Center for Genetic Disease, Principal Investigator and Director, Bahrain National Genome Program at Harvard and Assistant Professor of Medicine, Harvard Medical School, and Brigham and Women's Hospital

This is more than a regional milestone. It reflects our broader commitment to working with governments, academia, and industry worldwide to responsibly unlock the full potential of genomics and AI

Dr. Alireza Haghighi, my cofounder and I, are proud to announce an exciting partnership with Asia University to develop a "Sovereign AI Life Science Data Platform for Taiwan", a national system for secure health data sharing, AI-powered analytics, and collaborative research

With ER-100 on track for human trials in Q1 2026, this program is moving quickly 💉👁️ Jerry McLaughlin, our CEO, and I are so grateful for the creativity, dedication, and persistence the board & entire R&D team led by Dr. Sharon Rosenzweig-Lipson

This adds to earlier data showing clear functional benefits in the eye. They also beautifully match the mouse data we published in Nature (2020), in fact they are even more dramatic in their reversal of DNA methylation 😲 www.nature.com/articles/s41...

These results add to the weight of evidence that reprogramming is not just for age-reversal, it can be used to treat diseases that affect millions worldwide and with few effective treatments

In liver disease (MASH), ER-300, an AAV-delivered package of reprogramming genes, improved multiple key liver health biomarkers in an animal model, from ALT/AST to cholesterol and steatosis (fat content) scores

Said presenter and CSO, Sharon Rosenzweig-Lipson, "These results bring us closer to pioneering a new class of epigenetic therapies that can modify the biology of aging itself and, in doing so, transform how age-related diseases, such as optic neuropathies and MASH, are addressed”

Life Biosciences presented this new data
the ARDD conference in Copenhagen this week

This news is strong evidence that the original vision to develop therapies that reversal of aging to prevent and cure diseases of aging and injuries isn’t just a fanciful idea